Draft guide attempts to ease pharma worries over EMA-HTA advice
This article was originally published in SRA
The European Medicines Agency has released for consultation a draft guidance that seeks to boost the use of the parallel scientific advice procedure that the agency and national health technology (HTA) bodies offer drug companies1.
You may also be interested in...
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated to include a new product – Alnylam Pharmaceuticals' Givlaari for treating acute hepatic porphyria. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
The health technology assessment institute is taking a virtual approach to meetings and has said that it can provide free fast-track advice for companies developing novel diagnostics or therapeutics for the coronavirus.
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.